Clinical Trials | February 24, 2026
Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The NDA filing is supported by results from the phase III evERA Breast Cancer study
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
